Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Ullmann, U.
Right arrow Articles by Krausse, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ullmann, U.
Right arrow Articles by Krausse, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (1999) 43, Suppl. C, 33-36
© 1999 The British Society for Antimicrobial Chemotherapy

Comparative in-vitro activity of levofloxacin, other fluoroquinolones, doxycycline and erythromycin against Ureaplasma urealyticum and Mycoplasma hominis

U. Ullmann*, S. Schubert and R. Krausse

Department of Medical Microbiology and Virology, University of Kiel, Brunswiker Strasse 4, 24105 Kiel, Germany

The susceptibility of 56 Ureaplasma urealyticum and 57 Mycoplasma hominis strains to levofloxacin, ofloxacin, ciprofloxacin, fleroxacin, doxycycline and erythromycin was determined by an agar dilution method. The reference strain used was M. hominis PG 21. Agar plates containing serial dilutions of antibiotics (range 0.03-16 mg/L), and control plates (without antibiotics) were inoculated with bacteria suspended in modified Shepard's broth using a multipoint inoculator. Levofloxacin showed greater activity against all U. urealyticum and M. hominis strains compared with all other antibiotics tested. The MIC 90 values for U. urealyticum were as follows: levofloxacin, 1 mg/L; ofloxacin, 2 mg/L; ciprofloxacin, 4 mg/L; fleroxacin, 4 mg/L; doxycycline, 1 mg/L; erythromycin, 8 mg/L. The MIC 90s for M. hominis were: levofloxacin, 1 mg/L; ofloxacin, 2 mg/L; ciprofloxacin, 4 mg/L; fleroxacin, 4 mg/L; doxycycline, 4 mg/L; erythromycin, >=16 mg/L. In conclusion, the results of this study suggest that levofloxacin may be useful in the treatment of mycoplasma genital infections.

* Corresponding author. Tel: +49-431-597-3300; Fax: +49-431-597-2216.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Sex. Transm. Infect.Home page
C L Haggerty, P A Totten, S G Astete, S Lee, S L Hoferka, S F Kelsey, and R B Ness
Failure of cefoxitin and doxycycline to eradicate endometrial Mycoplasma genitalium and the consequence for clinical cure of pelvic inflammatory disease
Sex. Transm. Inf., October 1, 2008; 84(5): 338 - 342.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
N. Kechagia, S. Bersimis, and S. Chatzipanagiotou
Incidence and antimicrobial susceptibilities of genital mycoplasmas in outpatient women with clinical vaginitis in Athens, Greece
J. Antimicrob. Chemother., July 1, 2008; 62(1): 122 - 125.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
K. B. Waites, D. M. Crabb, X. Bing, and L. B. Duffy
In Vitro Susceptibilities to and Bactericidal Activities of Garenoxacin (BMS-284756) and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas
Antimicrob. Agents Chemother., January 1, 2003; 47(1): 161 - 165.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
C. M. Bebear, H. Renaudin, A. Bryskier, and C. Bebear
Comparative Activities of Telithromycin (HMR 3647), Levofloxacin, and Other Antimicrobial Agents against Human Mycoplasmas
Antimicrob. Agents Chemother., July 1, 2000; 44(7): 1980 - 1982.
[Abstract] [Full Text]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.